Cargando…

The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction

AIMS: Although inflammation plays an important role in the pathogenesis of heart failure (HF), the precise pathophysiological role of inflammation in HF with preserved left ventricular ejection fraction (HFpEF) still remains unclear. Hence, we examined the clinical significance of plasma neopterin,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Eiichiro, Hirata, Yoshihiro, Tokitsu, Takanori, Kusaka, Hiroaki, Tabata, Noriaki, Tsujita, Kenichi, Yamamuro, Megumi, Kaikita, Koichi, Watanabe, Hiroshi, Hokimoto, Seiji, Maruyama, Toru, Ogawa, Hisao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063166/
https://www.ncbi.nlm.nih.gov/pubmed/27774267
http://dx.doi.org/10.1002/ehf2.12070
_version_ 1782459920965173248
author Yamamoto, Eiichiro
Hirata, Yoshihiro
Tokitsu, Takanori
Kusaka, Hiroaki
Tabata, Noriaki
Tsujita, Kenichi
Yamamuro, Megumi
Kaikita, Koichi
Watanabe, Hiroshi
Hokimoto, Seiji
Maruyama, Toru
Ogawa, Hisao
author_facet Yamamoto, Eiichiro
Hirata, Yoshihiro
Tokitsu, Takanori
Kusaka, Hiroaki
Tabata, Noriaki
Tsujita, Kenichi
Yamamuro, Megumi
Kaikita, Koichi
Watanabe, Hiroshi
Hokimoto, Seiji
Maruyama, Toru
Ogawa, Hisao
author_sort Yamamoto, Eiichiro
collection PubMed
description AIMS: Although inflammation plays an important role in the pathogenesis of heart failure (HF), the precise pathophysiological role of inflammation in HF with preserved left ventricular ejection fraction (HFpEF) still remains unclear. Hence, we examined the clinical significance of plasma neopterin, an inflammatory biomarker, in HFpEF patients. METHODS AND RESULTS: In the present study, we recruited consecutive HFpEF patients hospitalized in Kumamoto University Hospital, and further measured plasma neopterin by high‐performance liquid chromatography and serum derivatives of reactive oxidative metabolites (DROM), a new biomarker of reactive oxygen species. Compared with risk factors (number of patients, age, sex, and equal incidence of diabetes mellitus, hypertension, and dyslipidemia) ‐matched non‐HF patients (n = 68), plasma neopterin levels, but not serum high‐sensitivity C‐reactive protein levels, were significantly increased in patients with HFpEF (n = 68) (P < 0.001 and P = 0.15, respectively), accompanied by an elevation in serum DROM levels (P < 0.001). Plasma neopterin levels in New York Heart Association (NYHA) class III/IV HFpEF patients were significantly higher than in NYHA class II patients (P < 0.004). Furthermore, plasma ln‐neopterin levels had significant and positive correlation with ln‐DROM values (r = 0.57) and parameters of cardiac diastolic dysfunction [the ratio of early transmitral flow velocity to tissue Doppler early diastolic mitral annular velocity (r = 0.34), left atrial volume index (r = 0.17), and B‐type natriuretic peptide (r = 0.38)]. Kaplan–Meier analysis showed that the high‐neopterin group (>51.5 nM: median value of neopterin in HFpEF patients) had a higher probability of cardiovascular events than the low‐neopterin group (log‐rank test, P = 0.003). CONCLUSIONS: Plasma neopterin levels significantly increased in HFpEF and correlated with the severity of HF. Furthermore, high neopterin were significantly correlated with future cardiovascular events, indicating that measurement of plasma neopterin might provide clinical benefits for risk stratification of HFpEF patients. © 2015 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
format Online
Article
Text
id pubmed-5063166
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50631662016-10-19 The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction Yamamoto, Eiichiro Hirata, Yoshihiro Tokitsu, Takanori Kusaka, Hiroaki Tabata, Noriaki Tsujita, Kenichi Yamamuro, Megumi Kaikita, Koichi Watanabe, Hiroshi Hokimoto, Seiji Maruyama, Toru Ogawa, Hisao ESC Heart Fail Short Communications AIMS: Although inflammation plays an important role in the pathogenesis of heart failure (HF), the precise pathophysiological role of inflammation in HF with preserved left ventricular ejection fraction (HFpEF) still remains unclear. Hence, we examined the clinical significance of plasma neopterin, an inflammatory biomarker, in HFpEF patients. METHODS AND RESULTS: In the present study, we recruited consecutive HFpEF patients hospitalized in Kumamoto University Hospital, and further measured plasma neopterin by high‐performance liquid chromatography and serum derivatives of reactive oxidative metabolites (DROM), a new biomarker of reactive oxygen species. Compared with risk factors (number of patients, age, sex, and equal incidence of diabetes mellitus, hypertension, and dyslipidemia) ‐matched non‐HF patients (n = 68), plasma neopterin levels, but not serum high‐sensitivity C‐reactive protein levels, were significantly increased in patients with HFpEF (n = 68) (P < 0.001 and P = 0.15, respectively), accompanied by an elevation in serum DROM levels (P < 0.001). Plasma neopterin levels in New York Heart Association (NYHA) class III/IV HFpEF patients were significantly higher than in NYHA class II patients (P < 0.004). Furthermore, plasma ln‐neopterin levels had significant and positive correlation with ln‐DROM values (r = 0.57) and parameters of cardiac diastolic dysfunction [the ratio of early transmitral flow velocity to tissue Doppler early diastolic mitral annular velocity (r = 0.34), left atrial volume index (r = 0.17), and B‐type natriuretic peptide (r = 0.38)]. Kaplan–Meier analysis showed that the high‐neopterin group (>51.5 nM: median value of neopterin in HFpEF patients) had a higher probability of cardiovascular events than the low‐neopterin group (log‐rank test, P = 0.003). CONCLUSIONS: Plasma neopterin levels significantly increased in HFpEF and correlated with the severity of HF. Furthermore, high neopterin were significantly correlated with future cardiovascular events, indicating that measurement of plasma neopterin might provide clinical benefits for risk stratification of HFpEF patients. © 2015 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. John Wiley and Sons Inc. 2015-11-09 /pmc/articles/PMC5063166/ /pubmed/27774267 http://dx.doi.org/10.1002/ehf2.12070 Text en © 2015 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Short Communications
Yamamoto, Eiichiro
Hirata, Yoshihiro
Tokitsu, Takanori
Kusaka, Hiroaki
Tabata, Noriaki
Tsujita, Kenichi
Yamamuro, Megumi
Kaikita, Koichi
Watanabe, Hiroshi
Hokimoto, Seiji
Maruyama, Toru
Ogawa, Hisao
The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction
title The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction
title_full The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction
title_fullStr The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction
title_full_unstemmed The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction
title_short The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction
title_sort clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction
topic Short Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063166/
https://www.ncbi.nlm.nih.gov/pubmed/27774267
http://dx.doi.org/10.1002/ehf2.12070
work_keys_str_mv AT yamamotoeiichiro theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT hiratayoshihiro theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT tokitsutakanori theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT kusakahiroaki theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT tabatanoriaki theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT tsujitakenichi theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT yamamuromegumi theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT kaikitakoichi theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT watanabehiroshi theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT hokimotoseiji theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT maruyamatoru theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT ogawahisao theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT yamamotoeiichiro clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT hiratayoshihiro clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT tokitsutakanori clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT kusakahiroaki clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT tabatanoriaki clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT tsujitakenichi clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT yamamuromegumi clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT kaikitakoichi clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT watanabehiroshi clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT hokimotoseiji clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT maruyamatoru clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction
AT ogawahisao clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction